{"id":59703,"date":"2026-03-17T13:18:24","date_gmt":"2026-03-17T05:18:24","guid":{"rendered":"https:\/\/flcube.com\/?p=59703"},"modified":"2026-03-17T13:18:25","modified_gmt":"2026-03-17T05:18:25","slug":"sino-biopharms-trd221-wins-nmpa-approval-novel-polysaccharide-drug-targets-osteoarthritis-via-complement-inhibition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59703","title":{"rendered":"Sino Biopharm&#8217;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that <strong>TRD221<\/strong>, a <strong>Category 1 innovative polysaccharide drug<\/strong> co-developed by subsidiary <strong>Tide Pharmaceutical<\/strong> and the <strong>Institute of Materia Medica (IMM)<\/strong> of the <strong>Chinese Academy of Medical Sciences<\/strong>, has received <strong>NMPA clinical trial approval<\/strong> for the treatment of <strong>osteoarthritis (OA)<\/strong>. The <strong>first-in-class complement cascade regulator<\/strong> inhibits <strong>inflammatory factor production<\/strong> to <strong>block direct chondrocyte attack<\/strong>, demonstrating <strong>dual pain relief and structural preservation<\/strong> in <strong>animal models<\/strong> with a <strong>favorable safety profile<\/strong>\u2014positioning TRD221 to address the <strong>significant unmet need<\/strong> for <strong>disease-modifying OA therapy<\/strong> beyond <strong>symptomatic pain management<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TRD221<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category 1 innovative polysaccharide drug \u2013 first-in-class<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Complement system cascade activation regulator; inhibits inflammatory factor production; protects chondrocytes<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Osteoarthritis<\/td><\/tr><tr><td><strong>Co-Developers<\/strong><\/td><td>Tide Pharmaceutical (Sino Biopharm subsidiary) + Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Dual action: pain relief + structural preservation; moves beyond symptomatic management<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>17\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>TRD221 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Chemical Structure<\/strong><\/td><td>Novel polysaccharide with unique composition<\/td><\/tr><tr><td><strong>Target Pathway<\/strong><\/td><td>Complement system cascade activation<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>\u2022 Inhibits complement-triggered inflammatory factor production<br>\u2022 Blocks direct attack and damage to chondrocytes (cartilage cells)<br>\u2022 Addresses OA pathology at the source<\/td><\/tr><tr><td><strong>Clinical Effects (Preclinical)<\/strong><\/td><td>\u2022 Pain symptom relief<br>\u2022 Structural damage improvement<br>\u2022 Favorable safety profile<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Disease-modifying osteoarthritis drug (DMOAD) candidate<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>[To be determined \u2013 likely oral or injectable]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complement in OA:<\/strong> Overactivation drives synovial inflammation, cartilage degradation, and chondrocyte death<\/li>\n\n\n\n<li><strong>Polysaccharide Advantage:<\/strong> Natural product-derived; potential for excellent tolerability and multi-target modulation<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved DMOADs; current therapies (NSAIDs, intra-articular injections) provide only symptomatic relief<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>OA Market Size<\/strong><\/td><td>China: 100+ million patients; 10% of adults &gt;45 years; fastest-growing musculoskeletal disease<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>NSAIDs (pain), intra-articular hyaluronic acid\/corticosteroids (symptomatic), joint replacement (end-stage)<\/td><\/tr><tr><td><strong>DMOAD Gap<\/strong><\/td><td>No approved therapies halt or reverse cartilage degradation; TRD221 targets structural preservation<\/td><\/tr><tr><td><strong>Academic Collaboration<\/strong><\/td><td>IMM partnership validates scientific rigor; Chinese Academy of Medical Sciences prestige enhances credibility<\/td><\/tr><tr><td><strong>Sino Biopharm Pipeline<\/strong><\/td><td>Diversifies beyond oncology (toripalimab) and hepatitis; establishes musculoskeletal franchise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>TRD221 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Pfizer\/Lilly<\/strong><\/td><td>Tanezumab<\/td><td>NGF inhibitor<\/td><td>Discontinued (safety)<\/td><td>Complement inhibition vs. pain pathway; potential for disease modification<\/td><\/tr><tr><td><strong>Novartis<\/strong><\/td><td>LNA043 (sprifermin)<\/td><td>FGF-18 growth factor<\/td><td>Phase III<\/td><td>Polysaccharide complement regulator vs. growth factor; different biology<\/td><\/tr><tr><td><strong>Samumed<\/strong><\/td><td>Lorecivivint<\/td><td>Wnt pathway modulator<\/td><td>Phase III (failed 2022)<\/td><td>Novel mechanism; Chinese innovation<\/td><\/tr><tr><td><strong>Sino Biopharm<\/strong><\/td><td><strong>TRD221<\/strong><\/td><td><strong>Complement cascade polysaccharide inhibitor<\/strong><\/td><td><strong>Phase I-ready<\/strong><\/td><td><strong>First-in-class; dual pain\/structure benefit; natural product-derived<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2026-2027<\/td><td>Safety, tolerability, pharmacokinetics; biomarker validation (complement activation markers)<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2029<\/td><td>Efficacy in knee OA; pain scores (WOMAC); cartilage imaging (MRI); structural preservation endpoints<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2029-2032<\/td><td>Registrational studies vs. NSAIDs and placebo; joint replacement delay as hard endpoint<\/td><\/tr><tr><td><strong>Regulatory Strategy<\/strong><\/td><td>2032-2033<\/td><td>China NDA; potential for breakthrough therapy designation given DMOAD unmet need<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>2028+<\/td><td>U.S.\/EU IND preparation; partnership discussions for ex-China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, complement mechanism validation, and disease-modifying potential for TRD221 in osteoarthritis. Actual results may differ due to polysaccharide drug development complexity, OA clinical trial endpoint challenges, and competitive dynamics with other DMOAD candidates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59706,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,908,313,3531],"class_list":["post-59703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-sino-biopharmaceutical","tag-tide-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharm&#039;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59703\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharm&#039;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59703\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T05:18:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T05:18:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharm&#8217;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition\",\"datePublished\":\"2026-03-17T05:18:24+00:00\",\"dateModified\":\"2026-03-17T05:18:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703\"},\"wordCount\":546,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1701.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"Sino Biopharmaceutical\",\"Tide Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59703#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59703\",\"name\":\"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1701.webp\",\"datePublished\":\"2026-03-17T05:18:24+00:00\",\"dateModified\":\"2026-03-17T05:18:25+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59703\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59703#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharm&#8217;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59703","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.","og_url":"https:\/\/flcube.com\/?p=59703","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-17T05:18:24+00:00","article_modified_time":"2026-03-17T05:18:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59703#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59703"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharm&#8217;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition","datePublished":"2026-03-17T05:18:24+00:00","dateModified":"2026-03-17T05:18:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59703"},"wordCount":546,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59703#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","keywords":["Clinical trial approval \/ initiation","HKG: 1177","Sino Biopharmaceutical","Tide Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59703#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59703","url":"https:\/\/flcube.com\/?p=59703","name":"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59703#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59703#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","datePublished":"2026-03-17T05:18:24+00:00","dateModified":"2026-03-17T05:18:25+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TRD221, a Category 1 innovative polysaccharide drug co-developed by subsidiary Tide Pharmaceutical and the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Sciences, has received NMPA clinical trial approval for the treatment of osteoarthritis (OA). The first-in-class complement cascade regulator inhibits inflammatory factor production to block direct chondrocyte attack, demonstrating dual pain relief and structural preservation in animal models with a favorable safety profile\u2014positioning TRD221 to address the significant unmet need for disease-modifying OA therapy beyond symptomatic pain management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59703#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59703"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59703#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","width":1080,"height":608,"caption":"Sino Biopharm's TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59703#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharm&#8217;s TRD221 Wins NMPA Approval \u2013 Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59703"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59703\/revisions"}],"predecessor-version":[{"id":59707,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59703\/revisions\/59707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59706"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}